Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.

Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group engages in the research, development, production, and sale of pharmaceutical products, focusing on oncology and central nervous system therapies. Self-described as a major player in the pharmaceutical industry.

msh id	COM:SIMCERE
symbol	2.1K
name	Simcere Pharmaceutical Group Limited
homepage url	https://www.simcere.com
country	CN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	7.03K
crunchbase url	-
linkedin url	-
founders	-

market cap	1.85B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.03
growth cost of revenue	0.23
growth depreciation and amortization	-0.08
growth ebitda	-0.14
growth ebitda ratio	-0.17
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.12
growth gross profit	-0
growth gross profit ratio	-0.05

2096

COM:SIMCERE

Simcere Pharmaceutical Group

Last Close

6.85

21/11 08:08

Market Cap

14.37B

Beta: -

Volume Today

3.77M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	813.84M
cost of revenue	813.84M
depreciation and amortization	28.79M
ebitda	130.03M
ebitda ratio	0.14
eps	0.04
eps diluted	0.04
operating expenses	589.43M
operating income	101.24M
operating income ratio	0.11

accounts receivables	-
capital expenditure	-
cash at beginning of period	229.11M
cash at end of period	229.11M
inventory	84.94M
working capital ttm	3.38B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-